OptimizeRx (NASDAQ:OPRX) Lowered to Hold Rating by Zacks Research

Zacks Research lowered shares of OptimizeRx (NASDAQ:OPRX) from a strong-buy rating to a hold rating in a report released on Monday morning,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Stifel Nicolaus cut their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Lake Street Capital cut their target price on OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Roth Mkm dropped their price target on OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Stephens lowered their target price on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday, March 6th. Finally, B. Riley Financial restated a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a research report on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $17.57.

OptimizeRx Stock Down 2.1%

OPRX stock opened at $6.63 on Monday. The firm has a market capitalization of $124.38 million, a PE ratio of 25.50 and a beta of 1.19. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a twelve month low of $5.54 and a twelve month high of $22.25. The stock’s 50 day moving average is $6.71 and its 200-day moving average is $11.40.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. Sell-side analysts expect that OptimizeRx will post 0.5 EPS for the current fiscal year.

OptimizeRx announced that its board has initiated a share buyback program on Thursday, March 5th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OPRX. Vanguard Group Inc. increased its holdings in OptimizeRx by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after acquiring an additional 138,224 shares during the last quarter. Royce & Associates LP lifted its holdings in OptimizeRx by 0.7% during the fourth quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock valued at $8,362,000 after purchasing an additional 4,700 shares during the last quarter. Kennedy Capital Management LLC boosted its position in OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after purchasing an additional 202,446 shares during the period. Rice Hall James & Associates LLC boosted its position in OptimizeRx by 8.2% during the fourth quarter. Rice Hall James & Associates LLC now owns 590,674 shares of the company’s stock worth $7,242,000 after purchasing an additional 44,858 shares during the period. Finally, Parkman Healthcare Partners LLC increased its stake in shares of OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after purchasing an additional 2,188 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.